{"name":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","slug":"jiangsu-yahong-meditech-co-ltd-aka-asieris","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"APL-1202 in combination with Epirubicin","genericName":"APL-1202 in combination with Epirubicin","slug":"apl-1202-in-combination-with-epirubicin","indication":"Other","status":"phase_3"},{"name":"APL-1401","genericName":"APL-1401","slug":"apl-1401","indication":"Other","status":"phase_1"},{"name":"ASN-3186","genericName":"ASN-3186","slug":"asn-3186","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"APL-1202 treatment","genericName":"APL-1202 treatment","slug":"apl-1202-treatment","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"Placebo in combination with Epirubicin","genericName":"Placebo in combination with Epirubicin","slug":"placebo-in-combination-with-epirubicin","indication":"Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"APL-1202 in combination with Epirubicin","genericName":"APL-1202 in combination with Epirubicin","slug":"apl-1202-in-combination-with-epirubicin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APL-1202 treatment","genericName":"APL-1202 treatment","slug":"apl-1202-treatment","phase":"phase_2","mechanism":"APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"APL-1401","genericName":"APL-1401","slug":"apl-1401","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASN-3186","genericName":"ASN-3186","slug":"asn-3186","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo in combination with Epirubicin","genericName":"Placebo in combination with Epirubicin","slug":"placebo-in-combination-with-epirubicin","phase":"phase_3","mechanism":"Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy.","indications":["Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOdEczMWw3N2ZRNzVDNHExNHBQd25GS1p5emtXaFNBTjBZX0pTUEZHMmg1d214OHA3ZXBKcG5JaXE3amNnYnFfX2pOeDk5TURncW9yTTBxWE1BWGcxMHFLYWFNZUZScDNLdGxlUTRyNE5RSkNKQzJvdGZFdHBENl94aHlCSmxNNDRoRG1SY0ZDeHU?oc=5","date":"2024-05-02","type":"pipeline","source":"Yahoo Finance","summary":"Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly","headline":"Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developin","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}